Literature DB >> 14570953

Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification.

Umesh N Khot1, Gang Jia, David J Moliterno, A Michael Lincoff, Monica B Khot, Robert A Harrington, Eric J Topol.   

Abstract

CONTEXT: In acute myocardial infarction, the presence and severity of heart failure at the time of initial presentation have been formally categorized by the Killip classification. Although well studied in ST-elevation myocardial infarction, the prognostic importance of Killip classification in non-ST-elevation acute coronary syndromes is not well established.
OBJECTIVES: To determine the prognostic importance of physical examination for heart failure analyzed according to Killip classification in non-ST-elevation acute coronary syndromes and to understand its predictive value relative to other variables. DESIGN, SETTING, AND PATIENTS: From April 2001 to September 2003, We analyzed information from 26 090 patients with non-ST-elevation acute coronary syndromes enrolled in the GUSTO IIb, PURSUIT, PARAGON A, and PARAGON B trials. Demographic information was categorized by Killip class. Killip classes III and IV were combined into 1 category. Multivariate Cox proportional hazard models were developed to determine the prognostic importance of Killip classification in comparison with other variables. MAIN OUTCOME MEASURE: Association between Killip classification and all-cause mortality at 30 days and 6 months.
RESULTS: Patients in Killip class II (n = 2513) and III/IV (n = 390) were older than those in Killip class I (n = 23 187), with higher rates of diabetes, prior myocardial infarction, ST depression, and elevated cardiac enzymes (all P<.001). Higher Killip class was associated with higher mortality at 30 days (2.8% in Killip class I vs 8.8% in class II vs 14.4% in class III/IV; P<.001) and 6 months (5.0% vs 14.7% vs 23.0%, respectively; P<.001). Patients with Killip class II, III, or IV constituted 11% of the overall population but accounted for approximately 30% of the deaths at both time points. In multivariate analysis, Killip class III/IV was the most powerful predictor of mortality at 30 days (hazard ratio [HR], 2.35; 95% confidence interval [CI], 1.69-3.26; P<.001) and 6 months (HR, 2.12; 95% CI, 1.63-2.75; P<.001). Killip class II was predictive of mortality at 30 days (HR, 1.73; 95% CI, 1.44-2.09; P<.001) and 6 months (HR, 1.52; 95% CI, 1.31-1.76; P<.001). Five factors-age, Killip classification, heart rate, systolic blood pressure, and ST depression-provided more than 70% of the prognostic information for 30-day and 6-month mortality.
CONCLUSIONS: Killip classification is a powerful independent predictor of all-cause mortality in patients with non-ST-elevation acute coronary syndromes. Age, Killip classification, heart rate, systolic blood pressure, and ST depression should receive particular attention in the initial assessment of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 14570953     DOI: 10.1001/jama.290.16.2174

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  30 in total

1.  Sex, Myocardial Infarction, and the Failure of Risk Scores in Women.

Authors:  Shilpa Agrawal; Jennifer Van Eyk; Kimia Sobhani; Janet Wei; C Noel Bairey Merz
Journal:  J Womens Health (Larchmt)       Date:  2015-08-19       Impact factor: 2.681

Review 2.  Explicit risk in acute coronary syndrome management.

Authors:  Merril L Knudtson; Colleen M Norris; P Diane Galbraith; Jaro Hubacek; William A Ghali
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

3.  Treatments and in-hospital mortality in acute myocardial infarction patients with rheumatoid arthritis: a nationwide retrospective cohort study in Japan.

Authors:  Toshiaki Isogai; Hiroki Matsui; Hiroyuki Tanaka; Naoto Yokogawa; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Clin Rheumatol       Date:  2017-01-26       Impact factor: 2.980

4.  The prognostic value of the nutritional prognostic index (NPI) and controlling nutritional status (CONUT) scoring systems in non-ST elevated myocardial infarction patients over 65 years of age.

Authors:  Bedrettin Boyraz; Ersin Ibisoglu; Burhan Aslan
Journal:  Aging Clin Exp Res       Date:  2022-01-07       Impact factor: 3.636

5.  Association of Prolonged Emergency Department Length of Stay with Adverse Events in Patients with Non-ST-Elevation Acute Coronary Syndrome.

Authors:  Thanya Limapichat; Sakarin Kaewyingyong
Journal:  Open Access Emerg Med       Date:  2022-03-10

6.  The use of risk scores for stratification of non-ST elevation acute coronary syndrome patients.

Authors:  Ramjane Khalill; Lei Han; Chang Jing; He Quan
Journal:  Exp Clin Cardiol       Date:  2009

Review 7.  Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?

Authors:  Ian J Sarembock; Dean J Kereiakes
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

8.  Gender-Specific Predictive Markers of Poor Prognosis for Patients with Acute Myocardial Infarction During a 6-Month Follow-up.

Authors:  Ping Wang; Jianhua Yao; Yuan Xie; Ming Luo
Journal:  J Cardiovasc Transl Res       Date:  2020-01-06       Impact factor: 4.132

9.  Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome.

Authors:  Raphaelle Dumaine; C Michael Gibson; Sabina A Murphy; Matthew Southard; Hung Q Ly; Carolyn H McCabe; Robert P Giugliano; Christopher P Cannon; Elliott M Antman; Eugene Braunwald
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-05       Impact factor: 3.738

10.  Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores.

Authors:  Krishna G Aragam; Umesh U Tamhane; Eva Kline-Rogers; Jin Li; Keith A A Fox; Shaun G Goodman; Kim A Eagle; Hitinder S Gurm
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.